TW201041857A - Stable forms of N-(2,6-dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide - Google Patents

Stable forms of N-(2,6-dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide Download PDF

Info

Publication number
TW201041857A
TW201041857A TW099114459A TW99114459A TW201041857A TW 201041857 A TW201041857 A TW 201041857A TW 099114459 A TW099114459 A TW 099114459A TW 99114459 A TW99114459 A TW 99114459A TW 201041857 A TW201041857 A TW 201041857A
Authority
TW
Taiwan
Prior art keywords
dimethyl
phenyl
compound
dimercapto
butanamine
Prior art date
Application number
TW099114459A
Other languages
English (en)
Chinese (zh)
Inventor
Svend Treppendahl
Karin Liltorp
Diego Heidi Lopez De
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42237259&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW201041857(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of TW201041857A publication Critical patent/TW201041857A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Cosmetics (AREA)
TW099114459A 2009-05-11 2010-05-06 Stable forms of N-(2,6-dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide TW201041857A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200900597 2009-05-11

Publications (1)

Publication Number Publication Date
TW201041857A true TW201041857A (en) 2010-12-01

Family

ID=42237259

Family Applications (1)

Application Number Title Priority Date Filing Date
TW099114459A TW201041857A (en) 2009-05-11 2010-05-06 Stable forms of N-(2,6-dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide

Country Status (23)

Country Link
EP (1) EP2430008A2 (fr)
JP (1) JP2012526152A (fr)
KR (1) KR20120022934A (fr)
CN (1) CN102459208A (fr)
AR (1) AR076556A1 (fr)
AU (1) AU2010246724B2 (fr)
BR (1) BRPI1013930A2 (fr)
CA (1) CA2761383A1 (fr)
CL (1) CL2011002814A1 (fr)
CO (1) CO6460741A2 (fr)
CR (1) CR20110590A (fr)
DO (1) DOP2011000351A (fr)
EA (1) EA201171381A1 (fr)
GE (1) GEP20146006B (fr)
IL (1) IL216148A0 (fr)
MA (1) MA33351B1 (fr)
MX (1) MX2011011885A (fr)
NZ (1) NZ596738A (fr)
SG (1) SG175968A1 (fr)
TN (1) TN2011000557A1 (fr)
TW (1) TW201041857A (fr)
WO (1) WO2010130260A2 (fr)
ZA (1) ZA201108112B (fr)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI349666B (en) * 2004-03-12 2011-10-01 Lundbeck & Co As H Substituted morpholine and thiomorpholine derivatives
DK2061465T3 (da) * 2006-08-23 2013-07-08 Valeant Pharmaceuticals Int Derivater af 4-(N-azacycloalkyl)anilider som kaliumkanalmodulatorer
NZ582942A (en) * 2007-08-01 2011-09-30 Lundbeck & Co As H Use of kncq potassium channel openers for treating attention deficit hyperactivity disorder (adhd) or aggression

Also Published As

Publication number Publication date
CL2011002814A1 (es) 2012-04-13
NZ596738A (en) 2013-04-26
GEP20146006B (en) 2014-01-10
ZA201108112B (en) 2013-01-30
DOP2011000351A (es) 2012-01-31
KR20120022934A (ko) 2012-03-12
CN102459208A (zh) 2012-05-16
SG175968A1 (en) 2011-12-29
AU2010246724A1 (en) 2011-12-08
WO2010130260A3 (fr) 2011-06-16
AR076556A1 (es) 2011-06-22
CO6460741A2 (es) 2012-06-15
BRPI1013930A2 (pt) 2019-09-24
IL216148A0 (en) 2012-01-31
WO2010130260A2 (fr) 2010-11-18
MA33351B1 (fr) 2012-06-01
MX2011011885A (es) 2011-12-06
EA201171381A1 (ru) 2012-05-30
WO2010130260A9 (fr) 2012-10-18
JP2012526152A (ja) 2012-10-25
AU2010246724B2 (en) 2013-03-21
TN2011000557A1 (en) 2013-05-24
EP2430008A2 (fr) 2012-03-21
CA2761383A1 (fr) 2010-11-18
CR20110590A (es) 2012-02-22

Similar Documents

Publication Publication Date Title
JP5841636B2 (ja) Ｓｅｒｔ、５−ｈｔ３および５−ｈｔ１ａの組み合わせた活性を有する化合物の治療的使用
JP6933964B2 (ja) ヘテロアリール化合物およびそれらの使用方法
US11738002B2 (en) Methods of treating neurological and psychiatric disorders
ES2968840T3 (es) Compuestos de aminocarbonilcarbamato y su uso en el tratamiento de trastornos hipercinéticos tales como el TDAH
JP2023530092A (ja) 精神障害又は精神高揚に有利なベンゾフラン組成物
BR112020011189A2 (pt) misturas não racêmicas e usos das mesmas
TW200848032A (en) Novel therapeutic uses of 4-[2-(4-methylphenylsulfanyl)phenyl]piperidine
JP2015199763A (ja) トランスノルセルトラリンの製剤、塩、及び多形体、並びにその使用
JP2024063076A (ja) シクロベンザプリン類似体及びアミトリプチレン類似体
EA015483B1 (ru) ПРИМЕНЕНИЕ ИНГИБИТОРА p38 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ПСИХИАТРИЧЕСКИХ РАССТРОЙСТВ
TW200938194A (en) Therapeutic uses of compounds having affinity to the serotonin transporter, serotonin receptors and noradrenalin transporter
TW201041857A (en) Stable forms of N-(2,6-dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide
US20050228052A1 (en) Methods of treating, preventing and managing a sleep disorder using (S)-didesmethylsibutramine
TW200817329A (en) Compounds with combined serotonin and norepinephrine reuptake inhibition
US20240366559A1 (en) Methods of treating neurological and psychiatric disorders
CN114761008B (zh) 用于在患有痴呆的患者中治疗行为和心理症状的方法
WO2022022651A1 (fr) Composé pour la prévention et le traitement de troubles psychiatriques et son utilisation
US20100286138A1 (en) Stable forms of N-(2,6-Dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide
OA19696A (en) Stable Forms of N-(2,6-Dimethyl-4Morpholin-4-YL-Phenyl)-3, 3-DimethylButyramide
TW200808300A (en) Use of benzo-heteroaryl sulfamide derivatives for the treatment of disease modification/epileptogenesis
WO2009112541A2 (fr) [2-(6-fluoro-1h-indol-3-ylsulfanyl)benzyl]méthyl amine pour le traitement des troubles de l’humeur